Cumberland Pharmaceuticals, Inc.

Cumberland Pharmaceuticals, Inc. is considered overvalued due to high valuation ratios, such as a Price to Book Value of 3.04 and an EV to EBITDA of 34.34, alongside a negative ROCE of -19.13% and poor long-term returns, despite a recent impressive one-year return of 164.80%.

Cumberland Pharmaceuticals, Inc. is currently considered risky and overvalued, with a Price to Book Value of 3.04, an EV to EBITDA of 34.34, and a negative ROCE of -19.13%, indicating a higher risk profile compared to its peers despite a strong year-to-date return of 65.82%.

As of June 20, 2025, the trend is mildly bullish due to positive daily moving averages, though caution is warranted from mildly bearish weekly MACD and KST signals, while monthly indicators remain bullish despite a bearish monthly RSI.

As of March 2022, the management team of Cumberland Pharmaceuticals, Inc. includes A. Kazimi (Chairman and CEO), Martin Cearnal (Executive VP and Chief Commercial Officer), and several independent directors: Gordon Bernard, Joseph Galante, Jonathan Griggs, Joey Jacobs, and James Jones. This team provides executive leadership and governance for the company.

Cumberland Pharmaceuticals, Inc. is a micro-cap specialty pharmaceutical company focused on developing and commercializing branded prescription products. As of March 2025, it reported net sales of $12 million and a net profit of $1 million, with a market cap of $80.79 million.

As of Jun 18, Cumberland Pharmaceuticals, Inc. has a market capitalization of 80.79 million and reported net sales of 41.09 million with a net profit of -3.29 million over the latest four quarters. Shareholder's funds are 22.85 million, and total assets amount to 75.58 million.